Topical eye drops are a cornerstone in the treatment of many ocular diseases, yet traditional suspension formulations face significant limitations that can affect their efficacy, tolerability, and safety.
Marinosolv technology significantly extends ocular tissue penetration, enabling a faster onset of efficacy due to high bioavailability of active pharmaceutical ingredients, while enhancing tolerability and safety through a substantial reduction in dosage and minimized systemic exposure.
Tacrolimus - a highly active immunosuppressant
For treatment of inflammatory diseases of the anterior segment of the eye (eg. moderate to severe dry eye disease, atopic allergic keratoconjunctivitis, non-infectious anterior uveitis, herpetic stromal keratitis and others).
Marinosolv® enables Tacrolimus to achieve its full therapeutic potential even at very low concentrations. Tacrosolv is a patented, preservative-free ophthalmic prescription solution.
Tacrosolv is an investigational medicinal product to treat inflammatory diseases of the anterior segment of the eye, representing a novel a treatment option for ocular allergy, dry eye disease in patients not responding to tear substitutes.
Development status: Phase II results published
Based on the novel Marinosolv® enabled formulation it will be the the first and only tacrolimus-based solution in the topical anti-inflammatory field.
Currently, we are actively seeking strategic partners for local and regional licensing and commercialization.
